Procaine

Lore & Background

It was introduced into medical use by surgeon Heinrich Braun. Prior to its discovery, cocaine was a commonly used local anesthetic. Einhorn wished his new discovery to be used for amputations, but surgeons preferred general anesthesia; dentists, however, found it very useful. Procaine is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-amino benzoic acid (PABA), which is then excreted by the kidneys. Procaine can be synthesized in two ways: by the direct reaction of benzocaine with 2-diethylaminoethanol using sodium ethoxide-ethanol solution, or by oxidizing 4-nitrotoluene to 4-nitrobenzoic acid, reacting with thionyl chloride and then with 2-diethylaminoethanol to give Nitrocaine, followed by reduction of the nitro group by hydrogenation over Raney nickel catalyst.

Reader's Guide

Procaine holds historical significance as one of the first synthetic local anesthetics, replacing cocaine in many medical and dental applications. Although today it is used less frequently due to more effective and hypoallergenic alternatives like lidocaine, procaine remains in use therapeutically in some countries for its sympatholytic, anti-inflammatory, perfusion-enhancing, and mood-enhancing effects. As a vasodilator, procaine is often coadministered with epinephrine to induce vasoconstriction, reducing bleeding and prolonging anesthesia. It is also a DNA-demethylating agent with growth-inhibitory effects in human cancer cells, and a 1% injection has been recommended for treating extravasation complications and inadvertent intra-arterial injections. Procaine is an occasional additive in illicit street drugs, sold as cocaine or heroin. Its legacy includes the widespread recognition of the name Novocain, which in some regions is used generically for procaine.

Did You Know?

• Procaine is a vasodilator and is often coadministered with epinephrine to reduce bleeding and prolong anesthesia.

Clinical Applications and Indications

Procaine benzylpenicillin occupies a distinctive niche in infectious disease management, primarily administered as an intramuscular injection. Its approved indications span a broad spectrum of bacterial conditions, including syphilis, anthrax, diphtheria, pneumonia, cellulitis, erysipelas, mouth infections, and animal bites. In the United States, the injectable suspension known as Bicillin C-R combines benzathine penicillin with procaine penicillin, though it is explicitly not recommended for syphilis because it delivers only half the standard benzathine penicillin dose. This limitation has prompted serious medication errors when clinicians confused it with Bicillin L-A, leading manufacturers to print the warning "Not for the Treatment of Syphilis" in bold red lettering directly on syringe labels. Beyond syphilis, the formulation serves as a practical option for respiratory tract infections in patients unlikely to complete an oral course, and it is administered as a single intramuscular shot for strep throat alongside Pen V and erythromycin. It also functions as an adjunctive agent in anthrax management.

Mechanism of Action and Depot Pharmacology

The pharmacological design of procaine benzylpenicillin rests on a dual-molecule architecture. Chemically, it is a salt pairing benzylpenicillin with the local anesthetic procaine, and this union gives the compound deliberately weak solubility, necessitating preparation as a suspension. Once injected into muscle, the suspension establishes what pharmacologists call a tissue depot. Over an extended period, the salt gradually dissolves into surrounding interstitial fluid, releasing the two constituent molecules into their bioactive, oppositely charged forms. Procaine fulfills a dual role: it extends the duration of antibiotic release, making the combination long-acting, and it numbs the local area to mitigate the discomfort of the depot. Meanwhile, benzylpenicillin enters the bloodstream and targets bacterial cell walls, disrupting their structural maintenance and synthesis until the organisms undergo lysis. A common misnomer in medical literature describes this dissociation as "hydrolysis," but that term is inaccurate; no water is consumed and the individual molecules remain chemically unchanged. The process is purely a separation of ionic partners.

Safety Profile and Adverse Reactions

Although procaine benzylpenicillin is a life-saving antibiotic, its safety profile demands careful clinical judgment. The most frequently encountered issue is localized pain at the injection site, a predictable consequence of the intramuscular depot. More serious adverse events include disturbances in blood clotting, seizures, and central nervous system abnormalities, the latter particularly associated with high doses where excess procaine accumulates. Allergic reactions range from mild hypersensitivity to full anaphylaxis, and the drug is contraindicated in anyone with a documented history of penicillin or procaine allergy. When treating syphilis specifically, clinicians must anticipate a Jarisch–Herxheimer reaction, an acute inflammatory response triggered by the rapid death of spirochetes. On the reassuring side, evidence supports its relative safety during pregnancy and breastfeeding. The medication belongs to the broader penicillin and beta-lactam family, a classification that informs both its antibacterial mechanism and its cross-reactivity risk in sensitized patients.

Historical Introduction and Global Standing

Procaine benzylpenicillin was introduced for medical use in 1948, establishing a long-acting injectable option within the penicillin and beta-lactam family of medications. Its sustained clinical relevance is confirmed by its listing on the World Health Organization's List of Essential Medicines, a designation that signals its importance as a core therapeutic agent. The formulation also carries compendial status in the British Pharmacopoeia, a mark of recognized pharmaceutical quality. In the United States, it is marketed as Bicillin C-R, a 4-milliliter injectable suspension delivering 1.2 million units of benzathine penicillin alongside 1.2 million units of procaine penicillin. The similarity in naming between Bicillin C-R and Bicillin L-A has been the source of medication errors serious enough to prompt packaging redesigns, with the phrase "Not for the Treatment of Syphilis" now printed in red on both the Bicillin CR and Bicillin CR 900/300 syringe labels. Authoritative drug information for the compound is maintained through the U.S. National Library of Medicine's Drug Information Portal, providing prescribers with a reliable reference point.